Development of new RNAi medicine for the chronic hereditary muscular disorder

开发治疗慢性遗传性肌肉疾病的新型 RNAi 药物

• 批准号: 23792431
• 负责人: KINOUCHI Nao
• 金额: $ 2.75万
• 依托单位: The University of Tokushima
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23792431/
• 关键词: RNAi; 骨格筋; コラーゲン

We developed high special collagen of the certainty of the security supply that it was cheaper, and clinical application was possible as a substitute of atelocollagen where the effectiveness was confirmed as a siRNA introduction agent. The possibility that it was effective for the adjustment of the local skeletal muscle mass in the individual level was suggested when we introduced myostatin specific siRNA which was a skeletal muscle mass suppressor with this special collagen, and it was thought that we were connected for the development of the new cure for the chronicity hereditary muscular disorder in the future.

我们开发了更便宜、供应安全性高的特殊胶原蛋白，并且可以作为去端肽胶原蛋白的替代品进行临床应用，其作为 siRNA 引入剂的有效性得到了证实。当我们引入肌生长抑制素特异性 siRNA（一种具有这种特殊胶原蛋白的骨骼肌质量抑制剂）时，表明它对于调整个体水平的局部骨骼肌质量是有效的，并且人们认为我们与未来慢性遗传性肌肉疾病新疗法的开发有联系。